Joint Managing Director
Andrew has a background in Health Economics and Market Access, including roles in Policy Research and Market Access Consulting.
Most recently, he was a Managing Consultant with the Market Access Consulting team at Evidera, with responsibility for global pricing and market access strategies and value communication materials for new medicines. Andrew has worked across a wide range of disease areas and product types, including pharmaceuticals, medical devices and diagnostics. He has completed over 100 HEOR/market access projects, spanning commercial due diligence, global pricing strategies (including reference pricing), clinical/economic evidence development plans, HTA submissions and payer value communication resource development.
Andrew obtained his MSc Health Economics from the University of York, and has led a policy review at the Nova School of Business and Economics, Lisbon, regarding European Commission incentives for the development of orphan drugs.